8 stories from 4 sources
Supporting Articles
Summary
CRH is closing in on the purchase of Dallas-based Arcosa, a construction products company with a market value of nearly $7 billion. The deal would be the biggest acquisition in CRH's history.
Why it matters
The size and timing of this transaction could reset competitive dynamics in US building products and validate a higher valuation bar for infrastructure-exposed assets.
Summary
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion. The purchase adds Apogee's atopic dermatitis candidates and expands AbbVie's dermatology portfolio.
Why it matters
The deal signals AbbVie is using large M&A to secure future growth, with success hinging on pipeline delivery in a crowded dermatology market.
Summary
AbbVie agreed to buy Apogee Therapeutics for nearly $11 billion to add Apogee’s experimental atopic dermatitis drug to its pipeline. The deal extends AbbVie’s recent push to use M&A to refresh growth drivers.
Why it matters
It signals Big Pharma’s willingness to spend aggressively for pipeline assets that can replace aging blockbusters.
Summary
EasyJet shareholders are pressing Castlelake to raise its £4.7bn proposal, arguing the bid should increase to at least £7 per share. The investor push implies the current offer undervalues the company and risks failing to secure support.
Why it matters
The outcome will signal how much pricing power public-market shareholders can exert over private capital in large UK take-privates under tighter financing conditions.
Summary
EasyJet rejected three takeover proposals from Castlelake, including a latest offer valuing the airline at about £4.74 billion. Castlelake is now taking its proposal directly to EasyJet shareholders after the board said the bid undervalues the company.
Why it matters
A public end run around the board can force a sale process and reset valuations across the European airline sector.
A curated list of other prominent stories from this day.
Summary
Fathom disclosed that agents were emailed a plan outlining a three-pillar “everything home” ecosystem tied to a pending Bed Bath & Beyond acquisition. The pitch frames the deal as a way to expand beyond real estate transactions into broader home-related services and commerce.
Why it matters
Brokerages chasing platform revenue can change agent economics and capital requirements before the model proves it can scale.
Summary
Large pharmaceutical companies have accelerated acquisitions of biotech firms, pushing deal activity to levels not seen in several years. Buyers are moving quickly to secure pipelines and promising assets rather than waiting for late stage clinical readouts.
Why it matters
A faster M&A cycle will reset biotech valuations and determine which drug programs get funded, scaled, or shelved over the next 12 to 24 months.
Summary
Bain is using AI-assisted rapid prototyping to recreate acquisition targets’ software and test whether product features are actually defensible. The approach aims to separate real differentiation from marketing claims before bidding.
Why it matters
Faster, cheaper product replication could reset software M&A pricing by exposing which advantages are real and which are replicable.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!